Timing of invasive mechanical ventilation and death in critically ill adults with COVID-19: A multicenter cohort study

Author:

Green AdamORCID,Rachoin Jean-Sebastien,Schorr Christa,Dellinger Phil,Casey Jonathan D.,Park Isabel,Gupta Shruti,Baron Rebecca M.,Shaefi Shahzad,Hunter KrystalORCID,Leaf David E.ORCID,

Abstract

Purpose To investigate if the timing of initiation of invasive mechanical ventilation (IMV) for critically ill patients with COVID-19 is associated with mortality. Materials and methods The data for this study were derived from a multicenter cohort study of critically ill adults with COVID-19 admitted to ICUs at 68 hospitals across the US from March 1 to July 1, 2020. We examined the association between early (ICU days 1–2) versus late (ICU days 3–7) initiation of IMV and time-to-death. Patients were followed until the first of hospital discharge, death, or 90 days. We adjusted for confounding using a multivariable Cox model. Results Among the 1879 patients included in this analysis (1199 male [63.8%]; median age, 63 [IQR, 53–72] years), 1526 (81.2%) initiated IMV early and 353 (18.8%) initiated IMV late. A total of 644 of the 1526 patients (42.2%) in the early IMV group died, and 180 of the 353 (51.0%) in the late IMV group died (adjusted HR 0.77 [95% CI, 0.65–0.93]). Conclusions In critically ill adults with respiratory failure from COVID-19, early compared to late initiation of IMV is associated with reduced mortality.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference37 articles.

1. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US;S Gupta;JAMA Intern Med,2020

2. Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry;JP Domecq;Crit Care Med,2021

3. Dexamethasone in Hospitalized Patients with Covid-19;Recovery Collaborative Group;N Engl J Med,2021

4. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19;REMAP-CAP Investigators;N Engl J Med,2021

5. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses;WHO Solidarity Trial Consortium;Lancet,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3